Project description:Bacterial pneumonia is still a major cause of morbidity and mortality worldwide. One of the reasons for this may be the lack of accurate diagnostic tests that results in delayed identification of the causative agent and subsequent delay in initiating appropriate therapy. Therefore, there is an urgent need for new diagnostic tools for the rapid identification of the causative agent in bacterial pneumonia. Host biomarkers for early identification of etiology agents in bacterial pneumonia could assist in the development of those new diagnostic tools. The existing biomarkers such as procalcitonin and C-reactive protein for diagnosis of bacterial pneumonia are rather unspecific inflammatory markers and are not discriminatory between different infectious pathogens. In this regard, the objective of this study was the identification of host biomarkers which could distinguish pneumococcal pneumonia from staphylococcal pneumonia in an experimental murine infection model using RNA-Sequencing.
Project description:Methicillin-resistant Staphylococcus aureus is one of the major causative agents associated to infections with a high morbidity and mortality in hospitals worldwide. In previous studies, we reported that lignan 3'-demethoxy-6-O-demethylisoguaiacin isolated and characterized from Larrea tridentata showed the best activity towards methicillin-resistant S. aureus. Understanding of mechanism of action of drugs allows design drugs in a better way. Therefore, we employed microarray to obtain gene expression profile of methicillin-resistant S. aureus after exposure to 3'-demethoxy-6-O-demethylisoguaiacin. The results showed that lignan had an effect on cell membrane affecting proteins of the ATP-binding cassette (ABC) transport system causing bacteria death.
Project description:To our knowledge, we provide the first proteomics study of Bordetella parapertussis, one of the causative agents of whooping cough. We compared the identified proteins different to Bordetella pertussis, the other pathogen causing whooping cough. In addition, we extended the study to investigate the proteome response to iron limitation, a stress condition the pathogens face while infection.
Project description:Methicillin-resistant Staphylococcus aureus is one of the major causative agents associated to infections with a high morbidity and mortality in hospitals worldwide. In previous studies, we reported that lignan 3'-demethoxy-6-O-demethylisoguaiacin isolated and characterized from Larrea tridentata showed the best activity towards methicillin-resistant S. aureus. Understanding of mechanism of action of drugs allows design drugs in a better way. Therefore, we employed microarray to obtain gene expression profile of methicillin-resistant S. aureus after exposure to 3'-demethoxy-6-O-demethylisoguaiacin. The results showed that lignan had an effect on cell membrane affecting proteins of the ATP-binding cassette (ABC) transport system causing bacteria death. This study consisted of comparison of isolated RNA of MRSA not treated and MRSA treated with lignan 3'-demethoxy-6-O-demethylisoguaiacin. Both RNAs samples were differentially dyed with Cy3 and Cy5 during cDNA synthesis and hybridized on DNA chip. Afterwards, the chip was scanned in a GenePix 4000B scanner. The resulting gene expression profile was analyzed in databases for functional annotations to find a potential mechanism of the lignan in MRSA.
Project description:PD and HSMI are viral diseases that cause heavy damages in Atlantic salmon aquaculture. This study was performed to examine and compare the time-courses of transcriptome responses to the causative agents - salmon alphavirus (SAV) and piscine reovirus (PRV).
Project description:<p>Subspecies of the protozoan parasite <em>Trypanosoma brucei</em> are the causative agents of Human African Trypanosomiasis (HAT), a debilitating neglected tropical disease prevalent across sub-Saharan Africa. HAT case numbers have steadily decreased since the start of the century, and sustainable elimination of one form of the disease is in sight. However, key to this is the development of novel drugs to combat the disease. Acoziborole is a recently developed benzoxaborole, currently in advanced clinical trials, for treatment of stage 1 and stage 2 HAT. Importantly, acoziborole is orally bioavailable, and curative with one dose. Recent studies have made significant progress in determining the molecular mode of action of acoziborole. However, less is known about the potential mechanisms leading to acoziborole resistance in trypanosomes. In this study, an <em>in vitro</em> derived acoziborole-resistant (AcoR) cell line was generated and characterised. The AcoR line exhibited significant cross-resistance with the methyltransferase inhibitor sinefungin as well as hypersensitisation to known trypanocides. Interestingly, transcriptomics analysis of AcoR cells indicated the parasites had obtained a procyclic- or stumpy-like transcriptome profile, with upregulation of procyclin surface proteins as well as differential regulation of key metabolic genes known to be expressed in a life cycle-specific manner, even in the absence of major morphological changes. However, no changes were observed in transcripts encoding CPSF3, the recently identified protein target of acoziborole. The results suggest that generation of resistance to this novel compound <em>in vitro</em> can be accompanied by transcriptomic switches resembling a procyclic- or stumpy-type phenotype.</p>